Results 31 to 40 of about 939 (187)

Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data. [PDF]

Headache
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Giacon M, Terrazzino S.
europepmc   +2 more sources

CGRP-Targeted Therapy in Vestibular Migraine-How Strong Is the Evidence? [PDF]

Eur J Neurol
ABSTRACT Background Medications for migraine prevention targeting the calcitonin gene‐related peptide (CGRP) pathway have substantially reduced symptom burden in many patients that have failed previous treatment strategies. In contrast, data on treatment response to monoclonal antibodies (mAbs) or small molecule receptor antagonists (gepants) in ...
Tarnutzer AA, Castro Abarca P, Kaski D.
europepmc   +2 more sources

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

Neurology and Therapy, 2023
Introduction Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an acute treatment when used with an anti-calcitonin gene-related peptide (CGRP) monoclonal ...
Richard B. Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D. Ayasse, Weijie Poh, François Cadiou, Aubrey Manack Adams   +7 more
doaj   +1 more source

Effects of CYP3A4 and P-glycoprotein inhibition or induction on the pharmacokinetics of ubrogepant in healthy adults: Two phase 1, open-label, fixed-sequence, single-center, crossover trials

Cephalalgia Reports, 2021
Background: Ubrogepant is metabolized by cytochrome P450 3A4 (CYP3A4) and is a P-glycoprotein (P-gp) substrate. Objective: To assess effects of multiple-dose moderate-strong CYP3A4 and strong P-gp inhibitors and inducers on ubrogepant pharmacokinetic (PK)
Abhijeet Jakate, Ramesh Boinpally, Matthew Butler, Wendy Ankrom, Marissa F Dockendorf, Antonia Periclou   +5 more
doaj   +1 more source

Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered With Esomeprazole Magnesium [PDF]

Clinical Pharmacology in Drug Development, 2021
AbstractUbrogepant is a calcitonin gene–related peptide receptor antagonist for the acute treatment of migraine. Esomeprazole magnesium increases intragastric pH, which may affect oral ubrogepant absorption. This open‐label, nonrandomized, crossover trial evaluated esomeprazole magnesium's impact on the pharmacokinetics and safety of coadministered ...
Ramesh, Boinpally, Kaifeng, Lu
openaire   +2 more sources

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

The Journal of Headache and Pain, 2023
Background Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene–related peptide (CGRP) receptor antagonist ...
Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, Nicolai D. Ayasse, Daniel Serrano, Linda Davis, Katherine Sommer, Janette Contreras-De Lama, Richard B. Lipton   +8 more
doaj   +1 more source

New Gepants Against Acute Migraine A Systematic Review and Network Meta-Analysis

Amrita Journal of Medicine, 2021
Objectives: Recently two calcitonin gene-related peptide receptor antagonists (ubrogepant and rimegepant) were approved for the acute attack of migraine.
Dhyuti Gupta, Suryaprakash Dhaneria, Alok Singh   +2 more
doaj   +1 more source

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

The Journal of Headache and Pain, 2022
Background In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking.
Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, Stefan Wilhelm, Erin Johansson   +4 more
doaj   +1 more source

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials

The Journal of Headache and Pain, 2022
Background Triptans are the first-line option for the acute treatment of migraine attacks; however, triptans are contraindicated in people with certain underlying cardiovascular risk factors and are associated with inadequate efficacy or poor ...
Richard B. Lipton, Rashmi B. Halker Singh, Dennis A. Revicki, Sihui Zhao, Anand R. Shewale, Jordan E. Lateiner, David W. Dodick   +6 more
doaj   +1 more source

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults

Drugs in Context, 2022
Migraine headaches are widespread, debilitating and considered a main cause of disability worldwide. Symptoms of migraines include unilateral, pulsating pain that can last for hours to days, frequently associated with photophobia and phonophobia, nausea,
Eric R Ocheretyaner, Maria Kofman, Elaena Quattrocchi   +2 more
doaj   +1 more source